In the ever-changing landscape of healthcare technology, wearable gadgets could potentially prove to be a game changer in the area of neurological disorders, particularly those that present communication barriers. Consider a situation in which…
Continue Reading
AI startup Paige launched a new AI product this week. The New York City-based company unveiled an AI-powered biomarker module that the company says can evaluate more than 505 genes and identify 1,228 molecular…
Continue Reading
Dementia represents a significant global health challenge, with early screening during the preclinical stage being crucial for effective management. Traditional diagnostic biomarkers for Alzheimer’s Disease, the most common form of dementia, are limited by…
Continue Reading
Parkinson’s disease (PD) is a multifactorial neurodegenerative disorder with high prevalence among the elderly, primarily manifested by progressive decline in motor function. The aging global demographic and increased life expectancy have led to a…
Continue Reading
What You Should Know:
– GrayMatters Health (GMH), developer of non-invasive treatments based on proprietary brain biomarkers associated with mental health disorders, today announced it is expanding its U.S. footprint with additional clinics now offering…
Continue Reading
Multiple myeloma management requires a balance between maximizing survival, minimizing adverse events to therapy, and monitoring disease progression. While previous work has proposed data-driven models for individual tasks, these approaches fail to provide a…
Continue Reading
Digital biomarkers that remotely monitor symptoms have the potential to revolutionize outcome assessments in future disease-modifying trials in Parkinson’s disease (PD), by allowing objective and recurrent measurement of symptoms and signs collected in the…
Continue Reading
Gait impairments are among the most common and disabling symptoms of Parkinson’s disease and worsen as the disease progresses. Early detection and diagnosis of subtype-specific gait deficits, as well as progression monitoring, can help…
Continue Reading
The current prostate cancer (PCa) screen test, prostate-specific antigen (PSA), has a high sensitivity for PCa but low specificity for high-risk, clinically significant PCa (csPCa), resulting in overdiagnosis and overtreatment of non-csPCa. Early identification…
Continue Reading
Wearable sensor technologies are becoming increasingly relevant in health research, particularly in the context of chronic disease management. They generate real-time health data that can be translated into digital biomarkers, which can provide insights…
Continue Reading
